High Efficacy of CD7 CAR-T Therapy for B-Cell Malignancies: A Breakthrough in Cancer Treatment

The latest research highlights the efficacy and safety of CD7 CAR-T cell therapy in treating relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Conducted by BIOOCUS in collaboration with Lu Daopei Hospital, the study demonstrates promising outcomes for patients, offering a powerful alternative to conventional chemotherapy.

In an exciting development for Cancer Treatment, BIOOCUS, in partnership with Lu Daopei Hospital, has unveiled groundbreaking research on the application of CD7 chimeric antigen receptor (CAR) T-cell therapy. This novel approach, targeting relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and T-cell lymphoblastic lymphoma (T-LBL), demonstrates high efficacy and safety, significantly improving patient outcomes.

The study, published in a prestigious journal, involved a parallel comparison of patients receiving CD7 CAR-T therapy followed by consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) against those treated with chemotherapy prior to transplantation. The research findings show that the patients who achieved complete remission (CR) with CD7 CAR-T therapy had comparable long-term survival outcomes to those treated with conventional chemotherapy. Importantly, the study found no significant increase in post-transplant complications, such as graft-versus-host disease (GVHD), infections, or other adverse events.

Key highlights of the study include:

• Complete Remission Rate: The CD7 CAR-T therapy showed an impressive complete remission rate, with over 97% of patients responding positively to the treatment.
• Safety Profile: Despite the innovative approach of using CAR-T therapy, the treatment was well-tolerated, with minimal side effects and no significant increase in high-grade GVHD or other severe complications.
• Post-Transplantation Success: Patients undergoing allo-HSCT after achieving CR with CD7 CAR-T therapy experienced favorable overall survival (OS) and leukemia-free survival (LFS), comparable to traditional chemotherapy-based treatments.

This research represents a significant milestone in the field of Cancer Immunotherapy, offering hope for patients with relapsed or refractory forms of leukemia and lymphoma. BIOOCUS remains committed to advancing the boundaries of CAR-T therapy, providing innovative solutions for patients who have exhausted conventional treatment options. As the world embraces these cutting-edge therapies, BIOOCUS is at the forefront of developing treatments that bring real change to patient outcomes.